Catalyst Wire Dossier Catalyst Wire Dossier

Allogeneic blood-derived natural killer cells

natural killer cells · NKGen Biotech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic blood-derived natural killer cells, covering 2024-11-20 to 2024-11-20. Get the full timeline:

Most recent: Clinical Trial Update: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy [Phase 1]

See pricing